Neuronetics (NASDAQ:STIM) Now Covered by Analysts at William Blair

Equities research analysts at William Blair started coverage on shares of Neuronetics (NASDAQ:STIM – Get Free Report) in a report issued on Monday, Briefing.com reports. The brokerage set an “outperform” rating on the stock.

A number of other brokerages have also recently commented on STIM. BTIG Research reiterated a “buy” rating and issued a $6.00 target price on shares of Neuronetics in a research report on Thursday, September 17th. Citigroup restated a “market outperform” rating on shares of Neuronetics in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research note on Monday, September 14th. Finally, B. Riley Financial increased their price objective on shares of Neuronetics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Friday, November 6th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $5.00.

Read Our Latest Stock Analysis on STIM

Neuronetics Price Performance

NASDAQ:STIM opened at $1.39 on Monday. The company has a debt-to-equity ratio of 2.76, a current ratio of 2.01 and a quick ratio of 1.82. The company has a 50 day moving average price of $2.35 and a 200-day moving average price of $1.87. Neuronetics has a 1-year low of $0.80 and a 1-year high of $3.44. The firm has a market cap of $108.04 million, a price-to-earnings ratio of -4.21 and a beta of 1.36.

Neuronetics (NASDAQ:STIM – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.07. The business had revenue of $41.96 million during the quarter, compared to analysts’ expectations of $40.42 million. Neuronetics had a negative return on equity of 102.23% and a negative net margin of 14.45%. Equities research analysts forecast that Neuronetics will post -0.30 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Jorey Chernett sold 2,187,051 shares of Neuronetics stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $1.15, for a total transaction of $2,515,108.65. Following the sale, the insider owned 7,325,577 shares in the company, valued at approximately $8,424,413.55. The trade was a 22.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 3,335,411 shares of company stock worth $4,479,146 over the last 90 days. 8.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Madryn Asset Management LP purchased a new position in Neuronetics during the second quarter worth about $24,102,634. Marshall Wace LLP boosted its holdings in Neuronetics by 219.5% in the 3rd quarter. Marshall Wace LLP now owns 1,551,840 shares of the company’s stock valued at $3,631,000 after purchasing an additional 1,066,148 shares in the last quarter. BlackRock Inc. purchased a new stake in Neuronetics in the 2nd quarter valued at approximately $776,000. FourWorld Capital Management LLC increased its position in Neuronetics by 59.9% during the 1st quarter. FourWorld Capital Management LLC now owns 1,489,322 shares of the company’s stock worth $2,160,000 after purchasing an additional 558,072 shares during the period. Finally, HighTower Advisors LLC increased its position in Neuronetics by 95.4% during the 3rd quarter. HighTower Advisors LLC now owns 1,101,502 shares of the company’s stock worth $2,578,000 after purchasing an additional 537,761 shares during the period. Institutional investors and hedge funds own 53.59% of the company’s stock.

About Neuronetics

(Get Free Report)

Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.

Featured Articles

Analyst Recommendations for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.